The Pharmaceuticals Export Promotion Council of India (Pharmexcil) has outlined a robust strategic roadmap for 2026, prioritising value-led growth, stronger regulatory capabilities and diversification into global markets. The vision was articulated during the council’s 21st Annual General Meeting (AGM) held on December 29, marking a significant moment in the evolution of India’s pharmaceutical exports.
Discussions at the AGM highlighted the industry’s transition from volume-driven exports to higher-value offerings such as complex generics, specialty active pharmaceutical ingredients (APIs) and advanced therapeutic platforms. Emphasis was placed on sustainable manufacturing practices, with flow chemistry, continuous processing and green chemistry emerging as critical enablers of quality, regulatory compliance and global competitiveness.
With increased focus on MSME empowerment, deeper regulatory engagement and expansion into non-traditional markets, the AGM reflected growing momentum and confidence in India’s pharmaceutical export ecosystem.
Also Read